Evidence map›Paper›PMID 40951566›Full record

ReviewArchives of Razi Institute2025

Manufacturing Technology and Effectiveness of Corona Vaccines: A Bibliometric Review.

S Rashki Ghalenoo, K Azhdari, F Khosravi, S Hamzeh, Z Bayat, M Talebi Mehrdar, N Dahmardeh, M Hassanshahian

Abstract readReview
In one paragraph

Review in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

S Rashki GhalenooDepartment of Cardiology, Zabol University of Medical Sciences, Zabol, Iran.
K AzhdariSchool of Public Health and Social Work, Faculty of Health, Queensland University of Technology, Brisbane, Australia.
F KhosraviDepartment of Biology, Faculty of Science, Shahid Bahonar University of Kerman, Kerman, Iran.
S HamzehMedical Student, Iran University of Medical Sciences, Tehran, Iran.
Z BayatDepartment of Biochemistry, Payame Noor University, Tehran, Iran.
M Talebi MehrdarDepartment of Basic Medical Sciences, University of Zabol.
N DahmardehDepartment of Basic Medical Sciences, University of Zabol.
M HassanshahianDepartment of Biology, Faculty of Science, Shahid Bahonar University of Kerman, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The etiology of "Covid-19," a respiratory illness, was first identified in late 2019 as the causative agent of the novel coronavirus. The conclusion of the pandemic was declared in 2023, and during this interval, a range of vaccines employing diverse strategies were developed. The effectiveness and other immunological characteristics of these vaccines have been thoroughly evaluated. The publication of documents related to the vaccines has persisted even after the conclusion of the pandemic. This study was conducted to investigate the research process and published documents related to the manufacturing technology and effectiveness of the vaccines. The documents published in the Scopus database in early 2024 were collected using restrictions in four subject areas and the English language. The bibliographic analysis was conducted using the Bibliometrix package in Rstudio and VOSviewer. A total of 2,810 documents were reviewed. The majority of these documents were articles and reviews, with 2,320 and 394 documents falling into these categories, respectively. Peptides and capillary electrophoresis emerged as prominent subjects in 2024. Furthermore, elasomeran, covilo, and tozinameran emerged as more recent than other keywords based on their temporal distribution. This study examines the documents published in one of the most reliable databases of vaccines against the novel strain of severe acute respiratory syndrome (SARS-CoV-2) from a bibliometric perspective. The findings of this study are expected to provide valuable insights and direction for future research initiatives, opportunities, and challenges in this field.

Indexed as

BibliometricsCOVID-19COVID-19 VaccinesVaccine EfficacyHumansSARS-CoV-2COVID-19 Vaccines2019-nCovBibliometricCOVID-19SARS-CoV-2Vaccine

Identifiers

PMID40951566
PMCPMC12426452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.